Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pramoxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 5/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.97 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.97 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.97 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.97 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.97 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.97 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.63 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | THRB | P10828 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramoxine SCHEMBL26020 | 0.98 | ALDH1A1 (1.00) | LMNAMAPK1USP2ALDH1A1HRH3 | |
| Pramoxine SCHEMBL4435138 | 0.95 | ALDH1A1 (0.94) | LMNAMAPK1USP2ALDH1A1HRH3 | |
| SCHEMBL23804878 | 0.94 | HRH3 (0.91) | LMNAMAPK1USP2ALDH1A1HRH3 | |
| SCHEMBL29508217 | 0.92 | ALDH1A1 (0.88) | LMNAMAPK1USP2ALDH1A1HRH3 | |
| Pramoxine SCHEMBL29048599 | 0.90 | ALDH1A1 (0.83) | LMNAMAPK1USP2ALDH1A1HRH3 | |
| Pramoxine SCHEMBL8189224 | 0.89 | LMNA (0.80) | LMNAMAPK1USP2ALDH1A1HRH3 | |
| SCHEMBL29508145 | 0.89 | ALDH1A1 (0.82) | LMNAMAPK1USP2ALDH1A1HRH3 | |
| SCHEMBL29508184 | 0.88 | ALDH1A1 (0.81) | LMNAMAPK1USP2ALDH1A1HRH3 | |
| SCHEMBL13186317 | 0.88 | HRH3 (0.80) | LMNAMAPK1USP2ALDH1A1HRH3 | |
| SCHEMBL23804879 | 0.87 | HRH3 (0.79) | LMNAMAPK1USP2ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3073 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027069-A1 | Compositions Comprising Pramoxine and Diphenydramine for Treatment of Skin Conditions | CRESTLINE DIRECT FINANCE, L.P., AS AGENT | 2026-01-29 | — | — | US | claimed |
| US-20250319103-A1 | COMPOSITIONS FOR TREATMENT OF ANAL GLAND DISEASE | CRESTLINE DIRECT FINANCE, L.P., AS AGENT | 2025-10-16 | — | — | US | claimed |
| US-12419959-B2 | Dermal skin protectant and carrier | Inspired Material Strategies, LLC (US) | 2025-09-23 | — | — | US | claimed |
| US-20250143905-A1 | TOPICAL TREATMENT FOR ANORECTAL DISORDERS WITH AND WITHOUT SEAT CUSHION | CUTLER ROBERT S (US) | 2025-05-08 | — | — | US | claimed |
| US-12285461-B2 | Topical antibiotic | CONCEPT MATRIX SOLUTIONS (US) | 2025-04-29 | — | — | US | claimed |
| CN-119367266-A | Method for preparing sterile compound multi-adhesive product and integrated production equipment thereof | 山东序列生物科技有限公司 | 2025-01-28 | — | — | CN | claimed |
| US-20240390300-A1 | ADVANCED METHOD AND KIT FOR WOUND TREATMENT | KENVUE BRANDS LLC | 2024-11-28 | — | — | US | claimed |
| WO-2024015597-A1 | COMPOSITIONS COMPRISING PRAMOXINE AND DIPHENYDRAMINE FOR TREATMENT OF SKIN CONDITIONS | VETNIQUE LABS, LLC (US) | 2024-01-18 | — | — | WO | claimed |
| WO-2023230175-A1 | COMPOSITIONS FOR TREATMENT OF ANAL GLAND DISEASE | VETNIQUE LABS, LLC (US) | 2023-11-30 | — | — | WO | claimed |
| US-20230293694-A1 | DERMAL SKIN PROTECTANT AND CARRIER | Inspired Material Strategies, LLC | 2023-09-21 | — | — | US | claimed |
| WO-1993024154-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES, LTD. (US) | 1993-12-09 | — | — | WO | claimed |
| WO-1993017655-A1 | TOPICAL AROMATIC RELEASING COMPOSITIONS | RICHARDSON VICKS INC. (US) | 1993-09-16 | — | — | WO | claimed |
| US-5196405-A | Sucralfate vehicle complexes tissue | Oskman, Norman H. (US) | 1993-03-23 | — | — | US | claimed |
| US-5002974-A | Oil phase with nonionic surfactant, water phase with thickener for emulsions for skin | WARNER-LAMBERT CO. (US) | 1991-03-26 | — | — | US | claimed |
| EP-0391905-A4 | HEMORRHOIDAL, OTHER COMPOSITIONS AND METHODS OF TREATMENT | — | 1991-01-02 | — | — | EP | claimed |
| EP-0391905-A1 | HEMORRHOIDAL, OTHER COMPOSITIONS AND METHODS OF TREATMENT. | PACKMAN ELIAS W (US) | 1990-10-17 | — | — | EP | claimed |
| US-4945084-A | Method and composition for topically treating anorectal or other dermal wounds | NORMAN OKSMAN (US) | 1990-07-31 | — | — | US | claimed |
| US-4877781-A | TIXOCORTOL PIVALATE, EPHEDRINE SULFATE, PRAMOXINE HYDROCHLORIDE; ANTIINFLAMMATORY AGENTS FOR HEMORRHOIDS | LaHaye, Peter G. (US) | 1989-10-31 | — | — | US | claimed |
| EP-0320254-A1 | Aqueous gels containing topical medicaments | THAMES PHARMACAL CO.INC. (US) | 1989-06-14 | — | — | EP | claimed |
| WO-1989000047-A1 | HEMORRHOIDAL, OTHER COMPOSITIONS AND METHODS OF TREATMENT | PACKMAN ELIAS W (US) | 1989-01-12 | — | — | WO | claimed |